Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

The study concluded that poly(propylene carbonate maleate) microspheres effectively encapsulated finasteride, achieving a biphasic release with prolonged drug release over 5-6 weeks in vitro.

This study found that topical finasteride and flutamide both significantly reduced sebaceous gland growth and decreased prostatic weights in hamsters, indicating systemic effects despite local application.

High doses of finasteride cause cell growth and tumors in mice.

In this study, the combination of finasteride and minoxidil significantly increased hair growth in balding male stumptail macaques compared to each drug alone.

This review discusses the use of antiandrogen therapy in dermatology, covering treatments for conditions like acne, hirsutism, and androgenic alopecia but reports no new clinical findings.

This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This study identified eight isoflavone derivatives as potential nonsteroidal inhibitors of rat 5α-reductase using a pharmacophore model in virtual screening.

In this preliminary study, women with facial hirsutism treated with topically applied finasteride cream showed a significant decrease in hair growth and thickness compared to placebo, without adverse effects.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

Finasteride affects prostate weights and pituitary activity differently with age.

This study reported that prenatal exposure to dihydrotestosterone altered long-term androgen metabolism in juvenile male rats, suggesting different regulatory mechanisms for 5a-reductase in hypothalamic versus pituitary tissues.

This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.

This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This study found that three months of oral finasteride treatment significantly decreased dihydrotestosterone levels and hair growth in hirsute women without negatively affecting gonadotropin secretion.

This study found that drying finasteride solvates at 85 °C for one day produced a metastable anhydrous form.

This study found that dutasteride completely suppressed the formation of 5alpha-dihydro metabolites in cultured human skin cells, suggesting its potential use in acne and androgenetic alopecia.

This study found that finasteride impaired stress reactivity and reduced exploratory and impulsive behaviors in rats, potentially by altering the hypothalamus-pituitary-adrenal axis function.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

This study reports that five new progesterone derivatives demonstrated inhibitory activity against the 5α-reductase enzyme and binding affinity for the androgen receptor in an in vitro hamster model.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This study developed a pharmacokinetic/pharmacodynamic model for finasteride, concluding that finasteride's nonlinear pharmacokinetics are likely due to its saturable binding to 5alphaR2.

This study describes a case where finasteride treatment for benign prostatic hypertrophy was associated with gynecomastia in a 62-year-old man, which resolved after the drug was discontinued.

This review discusses potential treatments for androgen excess in polycystic ovary syndrome and reports no new findings, emphasizing the importance of individualized antiandrogenic management to minimize side effects.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

Quickly get finasteride from tablets using easy methods.